 |
 |
SGN-75 is a humanized anti-CD70 monoclonal antibody attached to a potent, synthetic drug payload, monomethyl auristatin F (MMAF) utilizing Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. CD70 is expressed on a variety of solid tumors, including renal cell carcinoma, pancreatic, ovarian and lung cancer, as well as multiple myeloma and several types of non-Hodgkin lymphoma.
Single-agent dose-escalation trial assessing the safety, tolerability, pharmacokinetics and antitumor activity of SGN-75 in patients with metastatic renal cell carcinoma or relapsed or refractory non-Hodgkin lymphoma; enrollment to this trial is complete
If you have questions about the SGN-75 clinical trial, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.